Overview

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a first exploration of GLPG3970 in subjects with active primary Sjogren's Syndrome to evaluate the efficacy, safety and tolerability and determine its pharmacokinetics (PK) profile compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Galapagos NV